Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
LOS ANGELES - BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology company currently valued at $24.3 million, has announced its intention to merge with Streamex Exchange Corporation, a real-world asset tokenization firm, in a strategic all-stock transaction aimed at taking Streamex public on the Nasdaq. According to InvestingPro data, BioSig enters this merger with challenging financials, including a weak financial health score and current ratio of 0.15, indicating potential liquidity concerns. The Letter of Intent (LOI) outlines the proposed merger which would integrate Streamex’s commodity-focused tokenization and financing platform with BioSig’s existing operations. The announcement has sparked significant market interest, with BioSig’s stock showing a remarkable 31.73% return over the past week. InvestingPro subscribers have access to 12 additional key insights about BioSig’s market position and growth potential.
Streamex has developed a technology stack that includes primary issuance and decentralized exchange infrastructure for on-chain commodity markets. By leveraging blockchain technology, Streamex aims to enhance liquidity and efficiency in the commodity finance sector. The company’s co-founders, Henry McPhie and Morgan Lekstrom, have expressed their ambition to transform the traditional commodity and finance industries.
As part of the proposed merger, significant changes to BioSig’s board and management are expected. Henry McPhie is slated to become the new CEO and join the board, while Morgan Lekstrom is set to assume the role of Chairman. Anthony Amato, the current CEO and Chairman of BioSig, will maintain a position on the board. Additionally, strategic advisors, including Frank Giustra, Mathew August, and Mitchell Williams, will join the company post-transaction to provide expertise in commodities and U.S. capital markets.
Upon completion of the merger, Streamex’s current stockholders will own approximately 19.9% of BioSig’s outstanding common stock, which will increase to around 75% after accounting for the conversion of Series X Convertible Preferred Stock. The remaining equity will be held by BioSig’s current stakeholders.
The press release includes forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from the projected outcomes. BioSig has filed relevant information with the Securities and Exchange Commission, including risk factors in its Annual Report on Form 10-K.
This news is based on a press release statement from BioSig Technologies, Inc. The proposed merger is expected to expand market reach and capabilities, providing growth opportunities for both companies and their shareholders. With analysts anticipating sales challenges in the current year, this strategic move could be crucial for the company’s future growth trajectory. For detailed analysis and comprehensive financial metrics, investors can access advanced tools and insights through InvestingPro.
In other recent news, BioSig Technologies, Inc. has announced a change in its independent registered public accounting firm. Marcum LLP has resigned, and CBIZ CPAs P.C. has been appointed to take over the role. This transition follows CBIZ’s acquisition of Marcum’s attest business. Despite this change, BioSig’s previous reports did not contain any adverse opinions, although there were material weaknesses identified in internal controls. In another development, BioSig received a notification from the Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement, as its stock closed below $1.00 per share for 30 consecutive business days. The company has until October 8, 2025, to regain compliance or potentially face delisting. Additionally, BioSig has potentially met the stockholders’ equity requirement for continued listing on Nasdaq, following recent capital-raising efforts totaling approximately $4.85 million. The company is awaiting formal confirmation from Nasdaq regarding this compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.